

CORTELLIS COMPETITIVE INTELLIGENCE vs CORTELLIS DEALS INTELLIGENCE

30,000 MORE DEALS

Acorda Therapeutics to acquire BioTie Therapies																					
Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >																				
Drugs	MERGERS & ACQUISITION																				
Patents	SUMMARY																				
Contract																					
Events																					
Financial																					
Mergers & Acquisition																					
<ul style="list-style-type: none"> Summary Financial 																					
Sources																					
	<table> <tr> <td>Target (Principal Company)</td><td>BioTie Therapies Corp</td></tr> <tr> <td>Ownership</td><td>Public</td></tr> <tr> <td>Market Segment</td><td>Therapeutic products</td></tr> <tr> <td>Target Description</td><td>Biotie (NASDAQ: BITI) is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders.</td></tr> <tr> <td>Most Advanced Product</td><td>Launched</td></tr> <tr> <td>Leading Products</td><td>BTT-1023; SYN-120; tozadenant</td></tr> <tr> <td>Acquirer (Partner Company)</td><td>Acorda Therapeutics Inc</td></tr> <tr> <td>Prior Relationship</td><td>No</td></tr> <tr> <td>Attitude</td><td>Friendly</td></tr> <tr> <td>Major Investors</td><td>Baupost Group LLC; Deerfield Management Co; FMR LLC; Orbimed Advisors LLC; Versant Venture Management LLC</td></tr> </table>	Target (Principal Company)	BioTie Therapies Corp	Ownership	Public	Market Segment	Therapeutic products	Target Description	Biotie (NASDAQ: BITI) is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders.	Most Advanced Product	Launched	Leading Products	BTT-1023; SYN-120; tozadenant	Acquirer (Partner Company)	Acorda Therapeutics Inc	Prior Relationship	No	Attitude	Friendly	Major Investors	Baupost Group LLC; Deerfield Management Co; FMR LLC; Orbimed Advisors LLC; Versant Venture Management LLC
Target (Principal Company)	BioTie Therapies Corp																				
Ownership	Public																				
Market Segment	Therapeutic products																				
Target Description	Biotie (NASDAQ: BITI) is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders.																				
Most Advanced Product	Launched																				
Leading Products	BTT-1023; SYN-120; tozadenant																				
Acquirer (Partner Company)	Acorda Therapeutics Inc																				
Prior Relationship	No																				
Attitude	Friendly																				
Major Investors	Baupost Group LLC; Deerfield Management Co; FMR LLC; Orbimed Advisors LLC; Versant Venture Management LLC																				
	FINANCIAL																				
	<table> <tr> <td>Prior Year Total Revenue (USD million)</td><td>938.00</td></tr> <tr> <td>Cash on hand at Acquisition (USD million)</td><td></td></tr> <tr> <td>Shares Outstanding (million)</td><td>12.22</td></tr> <tr> <td>Offer Share Price (USD)</td><td>0.33</td></tr> <tr> <td>1-day Closing Share Price (USD)</td><td>13.20</td></tr> </table>	Prior Year Total Revenue (USD million)	938.00	Cash on hand at Acquisition (USD million)		Shares Outstanding (million)	12.22	Offer Share Price (USD)	0.33	1-day Closing Share Price (USD)	13.20										
Prior Year Total Revenue (USD million)	938.00																				
Cash on hand at Acquisition (USD million)																					
Shares Outstanding (million)	12.22																				
Offer Share Price (USD)	0.33																				
1-day Closing Share Price (USD)	13.20																				

Including 3,800 M&A Deals

29,000 CONTRACTS

AstraZeneca to develop Rigel's fostamatinib disodium worldwide

CONTRACT

EX-10.29 4 a10-5810_1ex10d29.htm EX-10.29
EXHIBIT 10.29

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

LICENSE AND COLLABORATION AGREEMENT

THIS LICENSE AND COLLABORATION AGREEMENT (the "Agreement") is entered into as of the Effective Date by and between RIGEL PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 1180 Veterans Boulevard, South San Francisco, CA 94080 ("Rigel") and ASTRAZENCA AB, a Swedish corporation having its principal place of business at SE-151-85, Södertälje, Sweden ("AZ"). Rigel and AZ are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

RECITALS

- I. AZ is a world leading pharmaceutical company.
- II. Rigel is a clinical-stage drug company.
- III. Rigel has developed, and owns, a novel drug product for the treatment of lymphoma, and immune thrombocytopenic purpura ("ITP").
- IV. AZ and Rigel desire to establish a strategic partnership.

NOW THEREFORE, in consideration of the foregoing premises,

ARTICLE 1

Article II

License

2.1 Grant to HMR.

- (a) Subject to the other provisions of this Agreement, VERTEX hereby grants to HMR an exclusive license or (as appropriate) sublicense under VERTEX Technology to the extent necessary to permit HMR to carry out its rights and obligations set forth in this Agreement and to develop, manufacture, have manufactured, market, use, sell and import for sale Compound, Bulk Drug Substance, Drug Product Candidates, and Drug Product in the Territory, with the right to sublicense only as set forth in (b) below. Notwithstanding the foregoing grant, VERTEX reserves the right to use all VERTEX Technology necessary to discharge its obligations and exercise its rights under this Agreement, including but not limited to its "Step-In" rights under Section 3.6 hereof and its Co-Promotion rights under Article V hereof. VERTEX retains all rights to VERTEX Technology except to the extent explicitly granted to HMR hereunder. The foregoing license shall not extend to the sale of

License, Development and Commercialization Agreement — Confidential — Page 9

Including unredacted agreements retrieved via FOIA request

DEAL OVERVIEWS

Acorda Therapeutics Inc Acquires BioTie Therapies Corp

Target Company
BioTie Therapies Corp

Deal Value (USD):
363.00M

Acquirer
Acorda Therapeutics Inc

Biotie (NASDAQ: BITI) is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders.

Market Segment:
Therapeutic products

Leading Technology:
Small molecule...more

Indication:
Alcoholism, Fibrosis,...more

Most Advanced Product:
Launched

Leading Products:
tozadenant, SYN-120,...

Prior Year Total Revenues (USD):
938.00M

Cash On Hand at Acquisition (USD):
-

Shares Outstanding:
12.22

Upfront Cash (USD):
363.00M

Contingent Payments (USD):
-

Offer Price Per Share:
0.33

Prior Close Sh. Price Premiums:
01% (1-Day): 13.20

05% (5-Day): 13.90

30% (30-Day): 14.68



THOMSON REUTERS

Announced: **01/19/2016**

Closed: **-**

ANALYSIS VIA CHARTS AND TABLES IN EXCEL FORMAT

Principal Company	Partner Company	Deal Start Date	Deal Title	Drugs Highest Status (Deal Start)	Total Projected Current (USD M)	Upfront Payment (USD Million To Principal - Current)
Covis Pharma Sarl	Concordia International	01-Mar-2015	Purchase of Covis Ph	Launched	1200	1200
AstraZeneca plc	Horizon Pharma plc	01-Nov-2013	Purchase of VIMOVO	Launched	295	35
BioTie Therapies Corp	Acorda Therapeutics	19-Jan-2016	Acorda Therapeutics	Launched	363	363
Ligand Pharmaceuticals	Eisai Co Ltd	07-Sep-2006	Eisai acquires oncolo	Launched	205	
Janssen Biotech Inc	Merck & Co Inc	03-Apr-1998	Schering-Plough to m	Pre-registration	50	20
Can-Fite BioPharma L	Cipher Pharmaceuticals	23-Mar-2015	Cipher Pharmaceuticals	Phase 3 Clinical	3.21	1.45
Rigel Pharmaceutical	AstraZeneca plc	16-Feb-2010	AstraZeneca to develo	Phase 3 Clinical	1245	100
Tobira Therapeutics Ir	Dong-A ST Co Ltd	11-Apr-2016	Dong-A to develop an	Phase 2 Clinical	3.5	0.5
Vertex Pharmaceuticals	Aventis Pharma AG	04-Sep-1993	Vertex and HMR to c	Phase 2 Clinical	232.5	20
Epimmune Inc	Pharmexa A/S	27-Jun-2001	Pharmexa to use Epi	Phase 2 Clinical	0.5	0.4
Amgen Inc	Roche Holding AG	22-May-1989	Synergen and Roche	Discovery	20	2
GenPharm International	Eisai Co Ltd	31-May-1993	GenPharm and Eisai	Discovery	30.5	0.5
3-Dimensional Pharm	Schering					
Novartis AG	Questcor					
Phytera Inc	Tsumura					
rEVO Biologics Inc	Merrimac					
University of Florida	Critical Th					

Average Deal Size



